Euroapi (XPAR:EAPI) Gross-Profit-to-Asset % : 5.41% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Euroapi Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Euroapi's annualized Gross Profit for the quarter that ended in Dec. 2024 was €88.8 Mil. Euroapi's average Total Assets over the quarter that ended in Dec. 2024 was €1,642.7 Mil. Therefore, Euroapi's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 5.41%.

Euroapi Gross-Profit-to-Asset % Historical Data

The historical data trend for Euroapi's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Euroapi Gross-Profit-to-Asset % Chart

Euroapi Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

5.69

6.77

10.54

9.83

9.18

Euroapi Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial					9.25	10.77	7.78	11.50	5.41

Competitive Comparison of Euroapi's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Euroapi's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Euroapi's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Euroapi's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Euroapi Gross-Profit-to-Asset % Calculation

Euroapi's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	142.4	/	( (1612.4	+	1489.5)	/ 2 )
	=	142.4	/	1550.95
	=	9.18 %

Euroapi's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	88.8	/	( (1795.9	+	1489.5)	/ 2 )
	=	88.8	/	1642.7
	=	5.41 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Euroapi Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Euroapi's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Euroapi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Euroapi SA (XPAR:EAPI) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

EAPIF:USA 0EAP:UK 940:Germany

Address

15 rue Traversiere, Paris, FRA, 75012

Website

https://www.euroapi.com

Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers. Geographically, the company generates maximum revenue from Europe, followed by North America, Asia-Pacific, and the Rest of the world.

Euroapi Headlines

No Headlines